Tags

Type your tag names separated by a space and hit enter

Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
J BUON. 2009 Oct-Dec; 14(4):635-9.JB

Abstract

PURPOSE

To examine the expression of the membrane markers of estrogen (ER) and progesterone receptors (PR), CA-125, CA 19-9 and HER2/neu in ovarian cancer tissues.

METHODS

Fifty-four samples of ovarian cancer tissues originating from 55 patients were examined by immunohistochemistry. Forty-three had serous papillary ovarian cancer, 9 of which were grade I, 12 grade II and 2 grade III. Twelve patients had a classic mucinous ovarian cancer, 5 of which were grade I, 4 grade II and 0 grade III.

RESULTS

Out of 43 patients with serous ovarian cancer, 7 expressed both steroid receptors, 22 had only one (10 ER and 12 PR), while 14 were negative. Only 2/12 patients with classic mucinous ovarian cancer expressed of both receptors. CA-125 was expressed in 37/43 patients with serous ovarian cancer and in 4/12 patients with classic mucinous ovarian cancer. CA 19-9 was expressed in 3/43 patients with serous ovarian cancer, and coexpressed with CA-125 in 2/3 patients. In patients with classic mucinous ovarian cancer, 4/12 had expression of CA 19-9 without coexpression with CA-125. HER2/neu positivity (3+) was proven in only one case with classic mucinous ovarian cancer, and any other expression (1+) in 7 additional patients (1 mucinous and 6 serous ovarian cancers).

CONCLUSION

Positive HER2/neu expression in the cells of ovarian cancer is very rare and HER2/neu overexpression is even rarer. Expression of ER and PR does not depend on tumor grade and/or at least not in grade I and II. Positive CA 19-9 expression may be present not only in cases of classic mucinous ovarian cancer but also in typical serous ovarian cancer. However, in the classic mucinous ovarian cancer, CA-125 may be expressed, though in relatively low percentage.

Authors+Show Affiliations

Clinic for Medical Oncology, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia. karafera@sbb.rsNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20148455

Citation

Karaferic, A, et al. "Expression of HER2/neu, Estrogen and Progesterone Receptors, CA 125 and CA19-9 On Cancer Cell Membrane in Patients With Serous and Mucinous Carcinoma of the Ovary." Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, vol. 14, no. 4, 2009, pp. 635-9.
Karaferic A, Jovanovic D, Jelic S. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary. J BUON. 2009;14(4):635-9.
Karaferic, A., Jovanovic, D., & Jelic, S. (2009). Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary. Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, 14(4), 635-9.
Karaferic A, Jovanovic D, Jelic S. Expression of HER2/neu, Estrogen and Progesterone Receptors, CA 125 and CA19-9 On Cancer Cell Membrane in Patients With Serous and Mucinous Carcinoma of the Ovary. J BUON. 2009 Oct-Dec;14(4):635-9. PubMed PMID: 20148455.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary. AU - Karaferic,A, AU - Jovanovic,D, AU - Jelic,S, PY - 2010/2/12/entrez PY - 2010/2/12/pubmed PY - 2010/3/10/medline SP - 635 EP - 9 JF - Journal of B.U.ON. : official journal of the Balkan Union of Oncology JO - J BUON VL - 14 IS - 4 N2 - PURPOSE: To examine the expression of the membrane markers of estrogen (ER) and progesterone receptors (PR), CA-125, CA 19-9 and HER2/neu in ovarian cancer tissues. METHODS: Fifty-four samples of ovarian cancer tissues originating from 55 patients were examined by immunohistochemistry. Forty-three had serous papillary ovarian cancer, 9 of which were grade I, 12 grade II and 2 grade III. Twelve patients had a classic mucinous ovarian cancer, 5 of which were grade I, 4 grade II and 0 grade III. RESULTS: Out of 43 patients with serous ovarian cancer, 7 expressed both steroid receptors, 22 had only one (10 ER and 12 PR), while 14 were negative. Only 2/12 patients with classic mucinous ovarian cancer expressed of both receptors. CA-125 was expressed in 37/43 patients with serous ovarian cancer and in 4/12 patients with classic mucinous ovarian cancer. CA 19-9 was expressed in 3/43 patients with serous ovarian cancer, and coexpressed with CA-125 in 2/3 patients. In patients with classic mucinous ovarian cancer, 4/12 had expression of CA 19-9 without coexpression with CA-125. HER2/neu positivity (3+) was proven in only one case with classic mucinous ovarian cancer, and any other expression (1+) in 7 additional patients (1 mucinous and 6 serous ovarian cancers). CONCLUSION: Positive HER2/neu expression in the cells of ovarian cancer is very rare and HER2/neu overexpression is even rarer. Expression of ER and PR does not depend on tumor grade and/or at least not in grade I and II. Positive CA 19-9 expression may be present not only in cases of classic mucinous ovarian cancer but also in typical serous ovarian cancer. However, in the classic mucinous ovarian cancer, CA-125 may be expressed, though in relatively low percentage. SN - 1107-0625 UR - https://www.unboundmedicine.com/medline/citation/20148455/Expression_of_HER2/neu_estrogen_and_progesterone_receptors_CA_125_and_CA19_9_on_cancer_cell_membrane_in_patients_with_serous_and_mucinous_carcinoma_of_the_ovary_ L2 - https://medlineplus.gov/ovariancancer.html DB - PRIME DP - Unbound Medicine ER -